Skip to main content
Fig. 1 | Clinical Epigenetics

Fig. 1

From: BRG1 knockdown inhibits proliferation through multiple cellular pathways in prostate cancer

Fig. 1

SMARCA4 (BRG1) is over expressed in prostate cancer. a SMARCA4 gene expression (logPRKM) in TCGA data (tumours n = 486, normal = 52) with tumour samples separated by molecular subtype defined by the TCGA. SMARCA4 expression is increased across all groups, with subtypes ERG, ETV1, ETV4, IDH1, SPOP and FOXA1 all significantly up-regulated, one-way ANOVA Dunnett’s multiple comparison correction **p < 0.05. b SMARCA4 gene expression in prostate cell lines normalised to 18S and relative to PrEC (n = 2). Significance determined by one-way ANOVA with Tukey’s multiple comparison correction ***p < 0.001. Bars denote mean, and error bars are SD. c Representative Western blot of BRG1 protein level in prostate cell lines. Quantification above Western blot by adjusted relative density normalised to GAPDH and relative to PrEC. d Expression of SMARCA4 from RNA-seq in prostate cell lines grouped as normal, cancer or transformed. The mean of each group was calculated, and a significance was tested by one-way ANOVA Dunnett’s multiple comparison correction, **p < 0.05

Back to article page
\